{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:04:54Z","timestamp":1789679094801,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03456-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:00:59Z","timestamp":1766563259000},"page":"768-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PaCE CKD: A Multinational Survey of Financial Burden and Work Productivity in Patients with Chronic Kidney Disease and Caregivers"],"prefix":"10.1007","volume":"43","author":[{"given":"Steven","family":"Chadban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham M.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-7769","authenticated-orcid":false,"given":"Juan Jose","family":"Garcia Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Pentakota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thames","family":"Kularatne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Fifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"11","key":"3456_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","volume":"34","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803\u20135.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3456_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"9","key":"3456_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3390\/healthcare9091212","volume":"9","author":"B Alshammari","year":"2021","unstructured":"Alshammari B, Noble H, McAneney H, Alshammari F, O\u2019Halloran P. Factors associated with burden in caregivers of patients with end-stage kidney disease (a systematic review). Healthcare. 2021;9(9):1212.","journal-title":"Healthcare"},{"issue":"3","key":"3456_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ajkd.2018.09.006","volume":"73","author":"EL Gilbertson","year":"2019","unstructured":"Gilbertson EL, Krishnasamy R, Foote C, Kennard AL, Jardine MJ, Gray NA. Burden of care and quality of life among caregivers for adults receiving maintenance dialysis: a systematic review. Am J Kidney Dis. 2019;73(3):332\u201343.","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"3456_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5414\/CNP86S113","volume":"86","author":"FJ Caskey","year":"2016","unstructured":"Caskey FJ. Prevalence and incidence of renal disease in disadvantaged communities in Europe. Clin Nephrol. 2016;86(13):34\u20136.","journal-title":"Clin Nephrol"},{"issue":"3","key":"3456_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ekir.2019.01.011","volume":"4","author":"DC Crews","year":"2019","unstructured":"Crews DC, Bello AK, Saadi G, et al. Burden, access, and disparities in kidney disease. Kidney Int Rep. 2019;4(3):372\u20139.","journal-title":"Kidney Int Rep"},{"key":"3456_CR7","unstructured":"United States Renal Data System. 2024 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2024."},{"issue":"5","key":"3456_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2021.04.011","volume":"78","author":"I Acquah","year":"2021","unstructured":"Acquah I, Valero-Elizondo J, Javed Z, et al. Financial hardship among nonelderly adults with CKD in the United States. Am J Kidney Dis. 2021;78(5):658\u201368.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3456_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12882-021-02552-2","volume":"22","author":"L Kirkeskov","year":"2021","unstructured":"Kirkeskov L, Carlsen RK, Lund T, Buus NH. Employment of patients with kidney failure treated with dialysis or kidney transplantation-a systematic review and meta-analysis. BMC Nephrol. 2021;22(1):348.","journal-title":"BMC Nephrol"},{"issue":"4","key":"3456_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semnephrol.2016.05.008","volume":"36","author":"V Wang","year":"2016","unstructured":"Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36(4):319\u201330.","journal-title":"Semin Nephrol"},{"issue":"3","key":"3456_CR11","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382\u201395.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"3456_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0004268","volume":"5","author":"DM Kelly","year":"2025","unstructured":"Kelly DM, Jones ESW, Barday Z, et al. Global availability of medications and health technologies for kidney care: a multinational study from the ISN-GKHA. PLOS Glob Public Health. 2025;5(2):e0004268.","journal-title":"PLOS Glob Public Health"},{"issue":"4","key":"3456_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100439","volume":"4","author":"SN Michalopoulos","year":"2022","unstructured":"Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, et al. Patient and care partner burden in CKD patients with and without anemia: a US-based survey. Kidney Med. 2022;4(4):100439.","journal-title":"Kidney Med"},{"issue":"1","key":"3456_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12882-021-02548-y","volume":"22","author":"EF de Vries","year":"2021","unstructured":"de Vries EF, Los J, de Wit GA, van Hakkaart- Roijen L. Patient, family and productivity costs of end-stage renal disease in the Netherlands; exposing non-healthcare related costs. BMC Nephrol. 2021;22(1):341.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3456_CR15","doi-asserted-by":"publisher","first-page":"sfae300","DOI":"10.1093\/ckj\/sfae300","volume":"17","author":"E Driehuis","year":"2024","unstructured":"Driehuis E, Janse RJ, Roeterdink AJ, et al. Informal caregiver burden in dialysis care and how it relates to patients\u2019 health-related quality of life and symptoms. Clin Kidney J. 2024;17(11):sfae300.","journal-title":"Clin Kidney J"},{"issue":"5","key":"3456_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3456_CR17","unstructured":"Reilly Associates. WPAI general information. 2019. http:\/\/www.reillyassociates.net\/wpai_general.html. Accessed 22\/08\/2023."},{"issue":"6","key":"3456_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1524-4733.2009.00542.x","volume":"12","author":"ER Giovannetti","year":"2009","unstructured":"Giovannetti ER, Wolff JL, Frick KD, Boult C. Construct validity of the work productivity and activity impairment questionnaire across informal caregivers of chronically ill older patients. Value Health. 2009;12(6):1011\u20137.","journal-title":"Value Health"},{"key":"3456_CR19","unstructured":"Consumer Financial Protection Bureau. Measuring financial well-being: a guide to using the CFPB Financial Well-being Scale. 2023. https:\/\/www.consumerfinance.gov\/data-research\/research-reports\/financial-well-being-scale\/. Accessed 22\/08\/2023."},{"issue":"3","key":"3456_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2017","unstructured":"de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial Toxicity (COST). Cancer. 2017;123(3):476\u201384.","journal-title":"Cancer"},{"key":"3456_CR21","unstructured":"FACIT.org. FACIT-COST: COST: a FACIT measure of financial toxicity. 2014. https:\/\/www.facit.org\/measures\/FACIT-COST. Accessed 22\/08\/2023."},{"issue":"1","key":"3456_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41687-024-00834-5","volume":"9","author":"MR Patel","year":"2025","unstructured":"Patel MR, Troost JP, Heisler M, Carlozzi NE. Clinically meaningful classes of financial toxicity for patients with diabetes. J Patient Rep Outcomes. 2025;9(1):2.","journal-title":"J Patient Rep Outcomes"},{"issue":"7","key":"3456_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"},{"issue":"7","key":"3456_CR24","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s12325-017-0566-z","volume":"34","author":"A Covic","year":"2017","unstructured":"Covic A, Jackson J, Hadfield A, Pike J, Siriopol D. Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease. Adv Ther. 2017;34(7):1662\u201372.","journal-title":"Adv Ther"},{"issue":"1","key":"3456_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","volume":"17","author":"D Eriksson","year":"2016","unstructured":"Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.","journal-title":"BMC Nephrol"},{"issue":"3","key":"3456_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.23876\/j.krcp.20.020","volume":"39","author":"HV Haalen","year":"2020","unstructured":"Haalen HV, Sloand J, Moon R, et al. Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data. Kidney Res Clin Pract. 2020;39(3):318\u201333.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"3456_CR27","doi-asserted-by":"publisher","first-page":"sfae341","DOI":"10.1093\/ckj\/sfae341","volume":"18","author":"A Hughes","year":"2024","unstructured":"Hughes A, Ju A, Cazzolli R, et al. Patient-reported outcome measures for life participation in patients with chronic kidney disease: a systematic review. Clin Kidney J. 2024;18(1):sfae341.","journal-title":"Clin Kidney J"},{"issue":"1","key":"3456_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3456_CR29","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2337\/dc22-0494","volume":"45","author":"MR Patel","year":"2022","unstructured":"Patel MR, Zhang G, Heisler M, et al. Measurement and validation of the comprehensive score for financial toxicity (COST) in a population with diabetes. Diabetes Care. 2022;45(11):2535\u201343.","journal-title":"Diabetes Care"},{"issue":"4","key":"3456_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/26350106241256324","volume":"50","author":"E Evans","year":"2024","unstructured":"Evans E, Jacobs M. Diabetes and financial well-being: differential hardship among vulnerable populations. Sci Diabetes Self Manag Care. 2024;50(4):263\u201374.","journal-title":"Sci Diabetes Self Manag Care"},{"issue":"1","key":"3456_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18865\/ed.34.1.41","volume":"34","author":"MM Jacobs","year":"2024","unstructured":"Jacobs MM, Evans E, Ellis C Jr. Financial well-being among US adults with vascular conditions: differential impacts among Blacks and Hispanics. Ethn Dis. 2024;34(1):41\u20138.","journal-title":"Ethn Dis"},{"issue":"18","key":"3456_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18189541","volume":"18","author":"MSN Ng","year":"2021","unstructured":"Ng MSN, Chan DNS, Cheng Q, Miaskowski C, So WKW. Association between financial hardship and symptom burden in patients receiving maintenance dialysis: a systematic review. Int J Environ Res Public Health. 2021;18(18):9541.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"3456_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1053\/j.ajkd.2021.02.327","volume":"78","author":"EA Brown","year":"2021","unstructured":"Brown EA, Zhao J, McCullough K, et al. Burden of kidney disease, health-related quality of life, and employment among patients receiving peritoneal dialysis and in-center hemodialysis: findings from the DOPPS program. Am J Kidney Dis. 2021;78(4):489-500.e1.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"3456_CR34","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/09567976241279203","volume":"35","author":"MD Kr\u00e4mer","year":"2024","unstructured":"Kr\u00e4mer MD, Bleidorn W. The well-being costs of informal caregiving. Psychol Sci. 2024;35(12):1382\u201394.","journal-title":"Psychol Sci"},{"issue":"6","key":"3456_CR35","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1007\/s10943-019-00939-y","volume":"59","author":"F Rafati","year":"2020","unstructured":"Rafati F, Mashayekhi F, Dastyar N. Caregiver burden and spiritual well-being in caregivers of hemodialysis patients. J Relig Health. 2020;59(6):3084\u201396.","journal-title":"J Relig Health"},{"issue":"1","key":"3456_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2021;99(1):34\u201347.","journal-title":"Kidney Int"},{"issue":"7","key":"3456_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385.","journal-title":"Nat Rev Nephrol"},{"key":"3456_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102614","volume":"72","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, Correa-Rotter R, Eckardt KU, et al. Projecting the clinical burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102614.","journal-title":"EClinicalMedicine"},{"key":"3456_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102615","volume":"72","author":"S Chadban","year":"2024","unstructured":"Chadban S, Ar\u0131c\u0131 M, Power A, et al. Projecting the economic burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102615.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"3456_CR40","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ekir.2025.01.020","volume":"10","author":"N Tangri","year":"2025","unstructured":"Tangri N, Oh K-H, Choo JCJ, et al. Inside CKD: cost-effectiveness of multinational screening for CKD. Kidney Int Rep. 2025;10(4):1087\u2013100.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"3456_CR41","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.ekir.2024.08.015","volume":"9","author":"S Brown","year":"2024","unstructured":"Brown S, Garcia Sanchez JJ, Guiang H, et al. IMPACT CKD: holistic disease model projecting 10-year population burdens. Kidney Int Rep. 2024;9(11):3156\u201366.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"3456_CR42","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.ekir.2025.03.051","volume":"10","author":"N Rao","year":"2025","unstructured":"Rao N, Brotons-Munto F, Moura AF, et al. Holistic impact of CKD: a clinical, economic, and environmental analysis by IMPACT CKD. Kidney Int Rep. 2025;10(7):2116\u201327.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"3456_CR43","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s13300-023-01464-8","volume":"14","author":"KC Ferdinand","year":"2023","unstructured":"Ferdinand KC, Norris KC, Rodbard HW, Trujillo JM. Humanistic and economic burden of patients with cardiorenal metabolic conditions: a systematic review. Diabetes Ther. 2023;14(12):1979\u201396.","journal-title":"Diabetes Ther"},{"issue":"20","key":"3456_CR44","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"6","key":"3456_CR45","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ndt\/gfv466","volume":"31","author":"JW Stanifer","year":"2016","unstructured":"Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31(6):868\u201374.","journal-title":"Nephrol Dial Transplant"},{"issue":"10225","key":"3456_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"2","key":"3456_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264393","volume":"17","author":"P Suriyong","year":"2022","unstructured":"Suriyong P, Ruengorn C, Shayakul C, Anantachoti P, Kanjanarat P. Prevalence of chronic kidney disease stages 3-5 in low- and middle-income countries in Asia: a systematic review and meta-analysis. PLoS ONE. 2022;17(2):e0264393.","journal-title":"PLoS ONE"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03456-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:33Z","timestamp":1771268613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03456-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3456"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03456-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steven Chadban has received payment\/honoraria from AstraZeneca, Boehringer Ingelheim, and Bayer for speaker fees and advisory boards. Ciro Esposito has received payment\/honoraria from AstraZeneca, Otsuka, Travere Therapeutics and Vifor Fresenius for speaker fees and advisory board. Ricardo Correa-Rotter has received honoraria as consultant from AstraZeneca, Boehringer Ingelheim, Bayer, Chinook, AbbVie, Novo Nordisk and Lilly, and research support from AstraZeneca, Boehringer Ingelheim, Roche, Lilly, Chinook and Novo Nordisk. He has received honoraria\/speaking fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Amgen. Mai-Szu Wu has received support from AstraZeneca for their contributions to this work, and payment\/honoraria for lectures, presentations, and manuscript writing. He has received payment\/honoraria from Baxter, Bayer, GSK, Novartis, Pfizer and Sanofi for lectures and presentations, and honoraria for advisory board participation from AstraZeneca, Bayer, GSK, Novartis and Sanofi. Helmut Reichel declares that he has no competing interests. Heschem M. Elsayed has received payment\/honoraria from AstraZeneca, Boehringer Ingelheim, Bayer, and GSK for symposia and is Emeritus Professor of Nephrology, ESNT President Elect, and Academic Director of RRT WKA Fellowship. Juan Jose Garcia Sanchez and Surendra Pentakota are employees of AstraZeneca. Thames Kularatne and Simon Fifer are employees of CaPPRe PTY Ltd. which received fees from AstraZeneca to conduct this study. CaPPRe has consulted to AbbVie, Amgen, Bristol Myers Squibb, Celgene, CSL Behring, Edwards LifeSciences, Gilead, GSK, Ipsen, Janssen, Medtronic, Novo Nordisk, Roche, Sanofi, Seqirus, Shire, UCB, and Vertex outside of the submitted work. Richard Hull has received speaking fees from AstraZeneca, Boehringer Ingelheim, Bayer and Thornton Ross Stada Group, and honoraria for advisory board participation from Novartis, Travere Therapeutics and Vifor Fresenius.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was reviewed by an international Institutional Review Board, Pearl IRB, and was granted an exemption from a full review due to its low\/negligible risk nature in accordance with FDA 21 56.104 and 45CFR46.104 (Protocol #21-CAPP-102). All participants provided electronic informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}